| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.024 | 0.4 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | 0.041 | 0.4 |